Catalyst is developing amifampridine phosphate for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also strives to treat other neuromuscular disorders such as congenital myasthenic syndromes and some cases of myasthenia gravis that are refractory to currently approved therapies.
Type
Public
HQ
Coral Gables, US
Founded
2002
Size (employees)
18 (est)
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, US
Report incorrect company information

Catalyst Pharmaceuticals Office Locations

Catalyst Pharmaceuticals has an office in Coral Gables
Coral Gables, US (HQ)
1250 355 Alhambra Cir
Show all (1)
Report incorrect company information

Catalyst Pharmaceuticals Financials and Metrics

Catalyst Pharmaceuticals Financials

USD

Net income (Q1, 2018)

(5.7 m)

EBIT (Q1, 2018)

(5.9 m)

Market capitalization (23-May-2018)

352.9 m

Closing share price (23-May-2018)

3.4

Cash (31-Mar-2018)

19.6 m
Catalyst Pharmaceuticals's current market capitalization is $352.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

4.5 m8.6 m7.9 m7.3 m

R&D expense

10.1 m11.8 m11.4 m11.4 m

Operating expense total

14.6 m20.4 m19.3 m18.7 m

EBIT

(14.6 m)(20.4 m)(19.3 m)(18.7 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

2.3 m2 m2.7 m2.3 m1.4 m1.9 m1.7 m2.7 m

R&D expense

2.6 m3 m3.5 m2.5 m2.5 m2.8 m2.5 m3.3 m

Operating expense total

4.9 m5 m6.2 m4.8 m3.9 m4.7 m4.2 m5.9 m

EBIT

(4.9 m)(5 m)(6.2 m)(4.8 m)(3.9 m)(4.7 m)(4.2 m)(5.9 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.2 m9.1 m28.2 m13.9 m57.5 m

Inventories

4.6 m1.5 m1 m

Current Assets

25.3 m43.8 m59.9 m41.5 m85.2 m

PP&E

40.6 k71.4 k191.5 k244.2 k191.4 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

41.3 m37.2 m32.8 m22.2 m18.7 m17.6 m10 m8.6 m19.6 m

Current Assets

76 m68.3 m64.4 m53.5 m48.7 m45.1 m37.5 m35.8 m78.9 m

PP&E

71.1 k63.3 k197.6 k178.4 k258.5 k249 k231.2 k218.3 k183.4 k

Total Assets

76 m68.3 m64.6 m53.7 m48.9 m45.3 m37.7 m36 m79.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(12.2 m)(15.5 m)(20.2 m)(18.1 m)(18.4 m)

Depreciation and Amortization

22.5 k26.6 k34.5 k43.4 k45.7 k

Accounts Payable

(514.9 k)963.4 k(20.1 k)(861 k)1 m

Cash From Operating Activities

(9.9 m)(12.9 m)(18 m)(18 m)(13.7 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(10 m)(14.4 m)(5.4 m)(10 m)(13.9 m)(5 m)(8.8 m)(5.7 m)

Depreciation and Amortization

17.1 k28.4 k13.2 k22 k31.4 k13 k25.9 k8 k

Accounts Payable

1.5 m932.1 k1.2 m524.8 k(497.9 k)(997.2 k)(542.7 k)(1.1 m)(738.8 k)(15.2 k)(240.8 k)(1.1 m)

Cash From Operating Activities

(8 m)(13.4 m)(5.9 m)(10.3 m)(13.6 m)(3.9 m)(7.1 m)(6.1 m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Catalyst Pharmaceuticals News and Updates

Report incorrect company information